- Home
- PGP vs BNR Comparison
PGP vs BNR Comparison
Compare PGP & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGP
- BNR
- Stock Information
- Founded
- PGP 2003
- BNR 2014
- Country
- PGP United States
- BNR China
- Employees
- PGP N/A
- BNR N/A
- Industry
- PGP Finance Companies
- BNR Medical Specialities
- Sector
- PGP Finance
- BNR Health Care
- Exchange
- PGP Nasdaq
- BNR Nasdaq
- Market Cap
- PGP 89.0M
- BNR 72.4M
- IPO Year
- PGP N/A
- BNR 2020
- Fundamental
- Price
- PGP $7.82
- BNR $6.53
- Analyst Decision
- PGP
- BNR
- Analyst Count
- PGP 0
- BNR 0
- Target Price
- PGP N/A
- BNR N/A
- AVG Volume (30 Days)
- PGP 39.8K
- BNR 28.7K
- Earning Date
- PGP 01-01-0001
- BNR 12-03-2024
- Dividend Yield
- PGP 10.84%
- BNR N/A
- EPS Growth
- PGP N/A
- BNR N/A
- EPS
- PGP N/A
- BNR N/A
- Revenue
- PGP N/A
- BNR $72,832,704.00
- Revenue This Year
- PGP N/A
- BNR $52.90
- Revenue Next Year
- PGP N/A
- BNR $48.35
- P/E Ratio
- PGP N/A
- BNR N/A
- Revenue Growth
- PGP N/A
- BNR N/A
- 52 Week Low
- PGP $5.83
- BNR $2.62
- 52 Week High
- PGP $7.81
- BNR $9.80
- Technical
- Relative Strength Index (RSI)
- PGP 47.96
- BNR 49.85
- Support Level
- PGP $7.55
- BNR $6.50
- Resistance Level
- PGP $7.91
- BNR $7.39
- Average True Range (ATR)
- PGP 0.15
- BNR 0.35
- MACD
- PGP 0.01
- BNR -0.14
- Stochastic Oscillator
- PGP 75.00
- BNR 25.41
About PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.